Compare WNEB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WNEB | CRVS |
|---|---|---|
| Founded | 1853 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.8M | 1.2B |
| IPO Year | 2001 | 2016 |
| Metric | WNEB | CRVS |
|---|---|---|
| Price | $13.55 | $11.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $13.67 | ★ $30.17 |
| AVG Volume (30 Days) | 31.9K | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | 33.93 | ★ 48.04 |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $44,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.25 | N/A |
| P/E Ratio | $56.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.53 | $3.55 |
| 52 Week High | $14.52 | $26.95 |
| Indicator | WNEB | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.55 | 43.20 |
| Support Level | $12.86 | $11.42 |
| Resistance Level | $14.22 | $14.00 |
| Average True Range (ATR) | 0.48 | 0.67 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 77.61 | 35.96 |
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.